Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis

Overview of attention for article published in Patient preference and adherence, October 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 15 publications that cite this research output.

15

The most recent citing publications are shown below. View all 15 publications that cite this research output on Dimensions.

Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations

Article in The International Journal of Neuropsychopharmacology (February 2024)

Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia

Article in CNS Drugs (January 2024)

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal

Article in Drug Healthcare and Patient Safety (September 2023)